Lilac Agriculture raises $2.3m to fix inoculant ‘black box’ problem
What's the deal? Lilac AgricultureDealroom has a profile for this one. Try Dealroom → has raised an oversubscribed $2.3 million seed round to develop next-generation rhizobial inoculants that help growers improve crop yields across varied soils. Innova led the round, with 701 FundDealroom has a profile for this one. Try Dealroom →, Ag Ventures AllianceDealroom has a profile for this one. Try Dealroom →, Evergreen Climate InnovationsDealroom has a profile for this one. Try Dealroom →, North Dakota Development Fund, Pathway VenturesDealroom has a profile for this one. Try Dealroom →, and Tall Grass VenturesDealroom has a profile for this one. Try Dealroom → participating.
What's the endgame? Founded in 2024 by researchers and agtech veterans from North Dakota State UniversityDealroom has a profile for this one. Try Dealroom →, Lilac is building a platform that optimises two traits at once: nitrogen-fixing efficiency and competitiveness. The money will advance that work.
Why it matters: Inoculating pulse crops with rhizobia is standard practice, but native soil bacteria often outcompete the inoculant. That leaves growers paying for a product that may not be working, chief executive officer Natalie DiNicola says.
How it works: Lilac screens the strain diversity in NDSU's collection for nitrogen fixation and competitiveness, using molecular markers to check which strains actually colonise roots and form nodules. Its first commercial strain, PL11, came from selecting the strongest naturally occurring strain, followed by a second phase of lab-driven "guided evolution."
The founder's view: "He felt like inoculants were sort of a black box; there wasn't a lot of transparency about what you were actually buying and if it was working," DiNicola says of co-founder Barney Geddes. Geddes, the company's chief scientific officer, dug up roots and found the bacteria in nodules were not those in the commercial products farmers had bought.
What could go wrong? Legacy suppliers have made significant advances in formulation and shelf-life, though DiNicola says less work has gone into improving the underlying biology of strains, many from older culture collections. Lilac's plant-breeding approach to microbes is unproven at commercial scale.
The signal: At $2.3 million, the round sits in the 34th percentile by size — modest, but reflecting investor appetite for biological inputs that promise measurable field results over trust-based claims. Applying breeding logic to microbes could push a decades-old category toward transparency growers have long asked for.
Read more: agfundernews.com
Image credit: Lilac Agriculture
